Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.

Herscu P, Handen BL, Arnold LE, Snape MF, Bregman JD, Ginsberg L, Hendren R, Kolevzon A, Melmed R, Mintz M, Minshew N, Sikich L, Attalla A, King B, Owley T, Childress A, Chugani H, Frazier J, Cartwright C, Murphy T; Autism Speaks Autism Clinical Trials Network.

J Autism Dev Disord. 2019 Jul 2. doi: 10.1007/s10803-019-04120-y. [Epub ahead of print]

PMID:
31267292
2.

Brief Report: Pilot Study of a Novel Interactive Digital Treatment to Improve Cognitive Control in Children with Autism Spectrum Disorder and Co-occurring ADHD Symptoms.

Yerys BE, Bertollo JR, Kenworthy L, Dawson G, Marco EJ, Schultz RT, Sikich L.

J Autism Dev Disord. 2019 Apr;49(4):1727-1737. doi: 10.1007/s10803-018-3856-7.

PMID:
30569407
3.

Parental concern regarding obesity in children with autism spectrum disorder in the United States: National Survey of Children's Health 2016.

Tybor DJ, Eliasziw M, Kral TVE, Segal M, Sherwood NE, Sikich L, Stanish H, Bandini L, Curtin C, Must A.

Disabil Health J. 2019 Jan;12(1):126-130. doi: 10.1016/j.dhjo.2018.09.004. Epub 2018 Sep 27.

PMID:
30352729
4.

The effects of intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder.

Greene RK, Spanos M, Alderman C, Walsh E, Bizzell J, Mosner MG, Kinard JL, Stuber GD, Chandrasekhar T, Politte LC, Sikich L, Dichter GS.

J Neurodev Disord. 2018 Mar 27;10(1):12. doi: 10.1186/s11689-018-9228-y.

5.

A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials.

Coates M, Spanos M, Parmar P, Chandrasekhar T, Sikich L.

Drug Saf. 2018 May;41(5):465-471. doi: 10.1007/s40264-017-0633-z. Review.

6.

Adaptive behavior in autism: Minimal clinically important differences on the Vineland-II.

Chatham CH, Taylor KI, Charman T, Liogier D'ardhuy X, Eule E, Fedele A, Hardan AY, Loth E, Murtagh L, Del Valle Rubido M, San Jose Caceres A, Sevigny J, Sikich L, Snyder L, Tillmann JE, Ventola PE, Walton-Bowen KL, Wang PP, Willgoss T, Bolognani F.

Autism Res. 2018 Feb;11(2):270-283. doi: 10.1002/aur.1874. Epub 2017 Sep 21.

7.

A Rural-Urban Comparison in Emergency Department Visits for U.S. Children with Autism Spectrum Disorder.

Zhang W, Mason AE, Boyd B, Sikich L, Baranek G.

J Autism Dev Disord. 2017 Mar;47(3):590-598. doi: 10.1007/s10803-016-2982-3.

PMID:
27909850
8.

The Effect of Age on the Prevalence of Obesity among US Youth with Autism Spectrum Disorder.

Must A, Eliasziw M, Phillips SM, Curtin C, Kral TV, Segal M, Sherwood NE, Sikich L, Stanish HI, Bandini LG.

Child Obes. 2017 Feb;13(1):25-35. doi: 10.1089/chi.2016.0079. Epub 2016 Oct 5.

9.

Intellectual disability is associated with increased risk for obesity in a nationally representative sample of U.S. children.

Segal M, Eliasziw M, Phillips S, Bandini L, Curtin C, Kral TV, Sherwood NE, Sikich L, Stanish H, Must A.

Disabil Health J. 2016 Jul;9(3):392-8. doi: 10.1016/j.dhjo.2015.12.003. Epub 2015 Dec 17.

10.
11.

Obesity Prevention for Children with Developmental Disabilities.

Must A, Curtin C, Hubbard K, Sikich L, Bedford J, Bandini L.

Curr Obes Rep. 2014 Jun;3(2):156-70. doi: 10.1007/s13679-014-0098-7.

12.

STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.

Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L, Scahill L, Cherubini M, Zarevics P, Walton-Bowen K, Carpenter RL, Bear MF, Wang PP, King BH.

J Autism Dev Disord. 2014 Apr;44(4):958-64. doi: 10.1007/s10803-013-1963-z.

PMID:
24272415
13.

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.

King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D.

JAMA Pediatr. 2013 Nov;167(11):1045-52. doi: 10.1001/jamapediatrics.2013.2698.

14.

Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?

Correll CU, Sikich L, Reeves G, Riddle M.

Am J Psychiatry. 2013 Sep;170(9):947-52. doi: 10.1176/appi.ajp.2013.13060771. No abstract available.

PMID:
24030606
15.

Does early mentorship in child and adolescent psychiatry make a difference? The Klingenstein Third-Generation Foundation Medical Student Fellowship Program.

Stein JA, Althoff R, Anders T, Davison Y, Edwards S, Frosch E, Horst R, Hudziak JJ, Hunt J, Joshi SV, Kitts RL, Larson J, Leckman J, O'Brien J, Lowenhaupt E, Pruitt D, Malloy E, Martin A, Partner A, Sarles R, Sikich L, Wells L, Kolevzon A.

Acad Psychiatry. 2013 Sep;37(5):321-4. doi: 10.1176/appi.ap.12070136.

PMID:
24026370
16.

Diagnosis and evaluation of hallucinations and other psychotic symptoms in children and adolescents.

Sikich L.

Child Adolesc Psychiatr Clin N Am. 2013 Oct;22(4):655-73. doi: 10.1016/j.chc.2013.06.005. Review.

PMID:
24012079
17.

Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: rationale, design, and methods.

Reeves GM, Keeton C, Correll CU, Johnson JL, Hamer RM, Sikich L, Hazzard L, Alderman C, Scheer A, Mabe M, Kapoor S, Sheridan E, Borner I, Bussell K, Pirmohamed S, Bethea TC, Chekuri R, Gottfried R, Reinblatt SP, Santana E, Riddle MA.

Child Adolesc Psychiatry Ment Health. 2013 Aug 15;7(1):31. doi: 10.1186/1753-2000-7-31.

18.

Should I stay or should I go now: when should clinicians try a different antipsychotic?

Sikich L.

J Am Acad Child Adolesc Psychiatry. 2013 Jul;52(7):677-8. doi: 10.1016/j.jaac.2013.04.019. No abstract available.

PMID:
23800480
19.

A+KIDS, a web-based antipsychotic registry for North Carolina youths: an alternative to prior authorization.

Christian RB, Farley JF, Sheitman B, McKee JR, Wei D, Diamond J, Chrisman A, Barnhill LJ Jr, Wegner L, Palmes G, Trygstad T, Pfeiffenberger T, Wegner SE, Best R, Sikich L.

Psychiatr Serv. 2013 Sep 1;64(9):893-900. doi: 10.1176/appi.ps.002762012.

PMID:
23728296
20.

Post-acute effectiveness of lithium in pediatric bipolar I disorder.

Findling RL, Kafantaris V, Pavuluri M, McNamara NK, Frazier JA, Sikich L, Kowatch R, Rowles BM, Clemons TE, Taylor-Zapata P.

J Child Adolesc Psychopharmacol. 2013 Mar;23(2):80-90. doi: 10.1089/cap.2012.0063.

21.

Exploring the manifestations of anxiety in children with autism spectrum disorders.

Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCracken JT, McDougle CJ, Tierney E, King BH, Hollander E, Sikich L, Bregman J, Anagnostou E, Donnelly C, Katsovich L, Dukes K, Vitiello B, Gadow K, Scahill L.

J Autism Dev Disord. 2013 Oct;43(10):2341-52. doi: 10.1007/s10803-013-1775-1.

22.

Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.

Frazier JA, Giuliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA, Hooper SR.

J Am Acad Child Adolesc Psychiatry. 2012 May;51(5):496-505. doi: 10.1016/j.jaac.2012.02.001. Epub 2012 Mar 13.

23.

Functional neuroimaging of treatment effects in psychiatry: methodological challenges and recommendations.

Dichter GS, Sikich L, Song A, Voyvodic J, Bodfish JW.

Int J Neurosci. 2012 Sep;122(9):483-93. doi: 10.3109/00207454.2012.678446. Epub 2012 Apr 30. Review.

24.

Pilot Study of an Active Screen Time Game Correlates with Improved Physical Fitness in Minority Elementary School Youth.

Bethea TC, Berry D, Maloney AE, Sikich L.

Games Health J. 2012 Feb;1(1):29-36. doi: 10.1089/g4h.2011.0005. Epub 2012 Jan 4.

25.

Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders.

Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, Bregman J, Sikich L, Dukes K, Sullivan L, Anagnostou E, Donnelly C, Kim YS, Ritz L, Hirtz D, Wagner A.

J Autism Dev Disord. 2012 Mar;42(3):432-40. doi: 10.1007/s10803-011-1251-8.

PMID:
21667200
26.

Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder.

Findling RL, Kafantaris V, Pavuluri M, McNamara NK, McClellan J, Frazier JA, Sikich L, Kowatch R, Lingler J, Faber J, Rowles BM, Clemons TE, Taylor-Zapata P.

J Child Adolesc Psychopharmacol. 2011 Jun;21(3):195-205. doi: 10.1089/cap.2010.0084.

27.
28.

Brain volumes in psychotic youth with schizophrenia and mood disorders.

El-Sayed M, Steen RG, Poe MD, Bethea TC, Gerig G, Lieberman J, Sikich L.

J Psychiatry Neurosci. 2010 Jul;35(4):229-36.

29.

First-dose pharmacokinetics of lithium carbonate in children and adolescents.

Findling RL, Landersdorfer CB, Kafantaris V, Pavuluri M, McNamara NK, McClellan J, Frazier JA, Sikich L, Kowatch R, Lingler J, Faber J, Taylor-Zapata P, Jusko WJ.

J Clin Psychopharmacol. 2010 Aug;30(4):404-10. doi: 10.1097/JCP.0b013e3181e66a62.

30.

Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.

Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L.

J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632. doi: 10.1016/j.jaac.2010.03.013. Epub 2010 May 1.

31.

Neurocognition in early-onset schizophrenia and schizoaffective disorders.

Hooper SR, Giuliano AJ, Youngstrom EA, Breiger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM, Vitiello B, Lieberman JA.

J Am Acad Child Adolesc Psychiatry. 2010 Jan;49(1):52-60.

32.

fMRI tracks reductions in repetitive behaviors in autism: two case studies.

Dichter GS, Sikich L, Mahorney S, Felder JN, Lam KS, Turner-Brown L, Bodfish J.

Neurocase. 2010 Aug;16(4):307-16. doi: 10.1080/13554790903559671. Epub 2010 Feb 22.

33.

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.

Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL.

Pediatrics. 2009 Dec;124(6):1533-40. doi: 10.1542/peds.2008-3782.

PMID:
19948625
34.

From bench to bedside: translating new research from genetics and neuroimaging into treatment development for early-onset schizophrenia.

Kumra S, Asarnow R, Grace A, Keshavan M, McClellan J, Sikich L, Wagner A.

Early Interv Psychiatry. 2009 Nov;3(4):243-58. doi: 10.1111/j.1751-7893.2009.00142.x. Review.

PMID:
22642727
35.

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L; STAART Psychopharmacology Network.

Arch Gen Psychiatry. 2009 Jun;66(6):583-90. doi: 10.1001/archgenpsychiatry.2009.30.

36.

A pilot of a video game (DDR) to promote physical activity and decrease sedentary screen time.

Maloney AE, Bethea TC, Kelsey KS, Marks JT, Paez S, Rosenberg AM, Catellier DJ, Hamer RM, Sikich L.

Obesity (Silver Spring). 2008 Sep;16(9):2074-80. doi: 10.1038/oby.2008.295.

37.

Mapping social target detection with functional magnetic resonance imaging.

Dichter GS, Felder JN, Bodfish JW, Sikich L, Belger A.

Soc Cogn Affect Neurosci. 2009 Mar;4(1):59-69. doi: 10.1093/scan/nsn037. Epub 2008 Nov 16.

38.

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA.

Am J Psychiatry. 2008 Nov;165(11):1420-31. doi: 10.1176/appi.ajp.2008.08050756. Epub 2008 Sep 15. Erratum in: Am J Psychiatry. 2008 Nov;165(11):1495.

PMID:
18794207
39.

The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation.

Findling RL, Frazier JA, Kafantaris V, Kowatch R, McClellan J, Pavuluri M, Sikich L, Hlastala S, Hooper SR, Demeter CA, Bedoya D, Brownstein B, Taylor-Zapata P.

Child Adolesc Psychiatry Ment Health. 2008 Aug 12;2(1):21. doi: 10.1186/1753-2000-2-21.

40.
41.

Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia.

Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, Nord AS, Kusenda M, Malhotra D, Bhandari A, Stray SM, Rippey CF, Roccanova P, Makarov V, Lakshmi B, Findling RL, Sikich L, Stromberg T, Merriman B, Gogtay N, Butler P, Eckstrand K, Noory L, Gochman P, Long R, Chen Z, Davis S, Baker C, Eichler EE, Meltzer PS, Nelson SF, Singleton AB, Lee MK, Rapoport JL, King MC, Sebat J.

Science. 2008 Apr 25;320(5875):539-43. doi: 10.1126/science.1155174. Epub 2008 Mar 27.

42.

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.

Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, Charles Schulz S.

Schizophr Bull. 2008 Jan;34(1):60-71. Epub 2007 Oct 8. Review.

43.

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics.

Frazier JA, McCLELLAN J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNAMARA NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L.

J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):979-988. doi: 10.1097/chi.0b013e31807083fd.

PMID:
17667477
44.

Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.

McCLELLAN J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA.

J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):969-978. doi: 10.1097/CHI.0b013e3180691779.

PMID:
17667476
45.

Early pharmacological treatment of autism: a rationale for developmental treatment.

Bethea TC, Sikich L.

Biol Psychiatry. 2007 Feb 15;61(4):521-37. Review. Erratum in: Biol Psychiatry. 2007 Mar 15;61(6):826.

46.

A comprehensive analysis of 22q11 gene expression in the developing and adult brain.

Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14433-8. Epub 2003 Nov 12.

47.

A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.

Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA.

Neuropsychopharmacology. 2004 Jan;29(1):133-45.

48.

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II.

Pappadopulos E, Macintyre Ii JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton CJ, Kranzler H, Rube DM, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS.

J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):145-61. Review.

PMID:
12544174
49.

Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review.

Schur SB, Sikich L, Findling RL, Malone RP, Crismon ML, Derivan A, Macintyre Ii JC, Pappadopulos E, Greenhill L, Schooler N, Van Orden K, Jensen PS.

J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):132-44. Review.

PMID:
12544173
50.

Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia.

Maynard TM, Sikich L, Lieberman JA, LaMantia AS.

Schizophr Bull. 2001;27(3):457-76. Review.

PMID:
11596847

Supplemental Content

Loading ...
Support Center